Request Free Sample ×
US Alpha Thalassemia Market Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Alpha Thalassemia Market

ID: MRFR/LS/17741-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Alpha Thalassemia Market Research Report By Type (hemoglobin Bart hydrops fetalis syndrome or Hb Bart syndrome, HbH disease, silent carrier state, trait), By Diagnosis (perinatal testing, prenatal testing, pre-implantation, complete blood count (CBC), DNA testing, prenatal genetic testing, chorionic villus sampling), By Treatment (blood transfusions, iron chelation, bone marrow or stem cell transplant, surgery, gene therapy) and By End-User (hospitals, biotechnological laboratories, diagnostic laboratories, educational research institutes, pharmaceutical industries, others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Alpha Thalassemia Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Type (USD Million)
  49.     4.1.1 Hb Bart syndrome
  50.     4.1.2 HbH disease
  51.     4.1.3 silent carrier state
  52.     4.1.4 trait
  53.   4.2 Construction, BY Diagnosis (USD Million)
  54.     4.2.1 perinatal testing
  55.     4.2.2 prenatal testing
  56.     4.2.3 pre-implantation
  57.   4.3 Construction, BY Treatment (USD Million)
  58.     4.3.1 blood transfusions
  59.     4.3.2 iron chelation
  60.     4.3.3 bone marrow or stem cell transplant
  61.     4.3.4 surgery
  62.     4.3.5 gene therapy
  63.   4.4 Construction, BY End-User (USD Million)
  64.     4.4.1 hospitals
  65.     4.4.2 biotechnological laboratories
  66.     4.4.3 diagnostic laboratories
  67.     4.4.4 educational research institutes
  68.     4.4.5 pharmaceutical industries
  69.     4.4.6 others
  70. 5 SECTION V: COMPETITIVE ANALYSIS
  71.   5.1 Competitive Landscape
  72.     5.1.1 Overview
  73.     5.1.2 Competitive Analysis
  74.     5.1.3 Market share Analysis
  75.     5.1.4 Major Growth Strategy in the Construction
  76.     5.1.5 Competitive Benchmarking
  77.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  78.     5.1.7 Key developments and growth strategies
  79.       5.1.7.1 New Product Launch/Service Deployment
  80.       5.1.7.2 Merger & Acquisitions
  81.       5.1.7.3 Joint Ventures
  82.     5.1.8 Major Players Financial Matrix
  83.       5.1.8.1 Sales and Operating Income
  84.       5.1.8.2 Major Players R&D Expenditure. 2023
  85.   5.2 Company Profiles
  86.     5.2.1 Novartis (CH)
  87.       5.2.1.1 Financial Overview
  88.       5.2.1.2 Products Offered
  89.       5.2.1.3 Key Developments
  90.       5.2.1.4 SWOT Analysis
  91.       5.2.1.5 Key Strategies
  92.     5.2.2 Bristol-Myers Squibb (US)
  93.       5.2.2.1 Financial Overview
  94.       5.2.2.2 Products Offered
  95.       5.2.2.3 Key Developments
  96.       5.2.2.4 SWOT Analysis
  97.       5.2.2.5 Key Strategies
  98.     5.2.3 Amgen (US)
  99.       5.2.3.1 Financial Overview
  100.       5.2.3.2 Products Offered
  101.       5.2.3.3 Key Developments
  102.       5.2.3.4 SWOT Analysis
  103.       5.2.3.5 Key Strategies
  104.     5.2.4 Pfizer (US)
  105.       5.2.4.1 Financial Overview
  106.       5.2.4.2 Products Offered
  107.       5.2.4.3 Key Developments
  108.       5.2.4.4 SWOT Analysis
  109.       5.2.4.5 Key Strategies
  110.     5.2.5 Roche (CH)
  111.       5.2.5.1 Financial Overview
  112.       5.2.5.2 Products Offered
  113.       5.2.5.3 Key Developments
  114.       5.2.5.4 SWOT Analysis
  115.       5.2.5.5 Key Strategies
  116.     5.2.6 GSK (GB)
  117.       5.2.6.1 Financial Overview
  118.       5.2.6.2 Products Offered
  119.       5.2.6.3 Key Developments
  120.       5.2.6.4 SWOT Analysis
  121.       5.2.6.5 Key Strategies
  122.     5.2.7 Sanofi (FR)
  123.       5.2.7.1 Financial Overview
  124.       5.2.7.2 Products Offered
  125.       5.2.7.3 Key Developments
  126.       5.2.7.4 SWOT Analysis
  127.       5.2.7.5 Key Strategies
  128.     5.2.8 Celgene (US)
  129.       5.2.8.1 Financial Overview
  130.       5.2.8.2 Products Offered
  131.       5.2.8.3 Key Developments
  132.       5.2.8.4 SWOT Analysis
  133.       5.2.8.5 Key Strategies
  134.     5.2.9 Vertex Pharmaceuticals (US)
  135.       5.2.9.1 Financial Overview
  136.       5.2.9.2 Products Offered
  137.       5.2.9.3 Key Developments
  138.       5.2.9.4 SWOT Analysis
  139.       5.2.9.5 Key Strategies
  140.   5.3 Appendix
  141.     5.3.1 References
  142.     5.3.2 Related Reports
  143. 6 LIST OF FIGURES
  144.   6.1 MARKET SYNOPSIS
  145.   6.2 US MARKET ANALYSIS BY TYPE
  146.   6.3 US MARKET ANALYSIS BY DIAGNOSIS
  147.   6.4 US MARKET ANALYSIS BY TREATMENT
  148.   6.5 US MARKET ANALYSIS BY END-USER
  149.   6.6 KEY BUYING CRITERIA OF CONSTRUCTION
  150.   6.7 RESEARCH PROCESS OF MRFR
  151.   6.8 DRO ANALYSIS OF CONSTRUCTION
  152.   6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  153.   6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  154.   6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
  155.   6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
  156.   6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
  157.   6.14 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
  158.   6.15 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
  159.   6.16 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
  160.   6.17 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
  161.   6.18 CONSTRUCTION, BY END-USER, 2024 (% SHARE)
  162.   6.19 CONSTRUCTION, BY END-USER, 2024 TO 2035 (USD Million)
  163.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  164. 7 LIST OF TABLES
  165.   7.1 LIST OF ASSUMPTIONS
  166.     7.1.1
  167.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  168.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  169.     7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  170.     7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  171.     7.2.4 BY END-USER, 2025-2035 (USD Million)
  172.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  173.     7.3.1
  174.   7.4 ACQUISITION/PARTNERSHIP
  175.     7.4.1

US Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

  • Hb Bart syndrome
  • HbH disease
  • silent carrier state
  • trait

Construction By Diagnosis (USD Million, 2025-2035)

  • perinatal testing
  • prenatal testing
  • pre-implantation

Construction By Treatment (USD Million, 2025-2035)

  • blood transfusions
  • iron chelation
  • bone marrow or stem cell transplant
  • surgery
  • gene therapy

Construction By End-User (USD Million, 2025-2035)

  • hospitals
  • biotechnological laboratories
  • diagnostic laboratories
  • educational research institutes
  • pharmaceutical industries
  • others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓